vs
NexPoint Real Estate Finance, Inc.（NREF）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
NexPoint Real Estate Finance, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.2倍（$11.1M vs $9.1M），NexPoint Real Estate Finance, Inc.净利率更高（216.6% vs -60.3%，领先277.0%），NexPoint Real Estate Finance, Inc.同比增速更快（-48.8% vs -49.9%）
NexPoint Real Estate Finance, Inc.是一家总部位于美国的商业地产金融企业，主要为多户住宅、写字楼、工业及酒店物业提供结构化融资方案，运营并管理抵押贷款及其他地产相关投资组合，为利益相关方提供经风险调整的稳定回报。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
NREF vs PLX — 直观对比
营收规模更大
NREF
是对方的1.2倍
$9.1M
营收增速更快
NREF
高出1.1%
-49.9%
净利率更高
NREF
高出277.0%
-60.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.1M | $9.1M |
| 净利润 | $24.0M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | — | -51.1% |
| 净利率 | 216.6% | -60.3% |
| 营收同比 | -48.8% | -49.9% |
| 净利润同比 | 58.7% | -184.8% |
| 每股收益（稀释后） | $0.47 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NREFPLX
| Q4 25 | $11.1M | $9.1M | ||
| Q3 25 | $12.5M | $17.9M | ||
| Q2 25 | $12.1M | $15.7M | ||
| Q1 25 | $11.5M | $10.1M | ||
| Q4 24 | $21.7M | $18.2M | ||
| Q3 24 | $12.5M | $18.0M | ||
| Q2 24 | $6.7M | $13.5M | ||
| Q1 24 | $-12.8M | — |
净利润NREFPLX
| Q4 25 | $24.0M | $-5.5M | ||
| Q3 25 | $50.9M | $2.4M | ||
| Q2 25 | $22.3M | $164.0K | ||
| Q1 25 | $26.0M | $-3.6M | ||
| Q4 24 | $15.2M | $6.5M | ||
| Q3 24 | $23.3M | $3.2M | ||
| Q2 24 | $12.1M | $-2.2M | ||
| Q1 24 | $-14.6M | — |
毛利率NREFPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率NREFPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
净利率NREFPLX
| Q4 25 | 216.6% | -60.3% | ||
| Q3 25 | 407.0% | 13.2% | ||
| Q2 25 | 184.5% | 1.0% | ||
| Q1 25 | 225.6% | -35.8% | ||
| Q4 24 | 69.9% | 35.6% | ||
| Q3 24 | 186.4% | 18.0% | ||
| Q2 24 | 179.7% | -16.4% | ||
| Q1 24 | 114.3% | — |
每股收益（稀释后）NREFPLX
| Q4 25 | $0.47 | $-0.06 | ||
| Q3 25 | $1.14 | $0.03 | ||
| Q2 25 | $0.54 | $0.00 | ||
| Q1 25 | $0.70 | $-0.05 | ||
| Q4 24 | $0.71 | $0.10 | ||
| Q3 24 | $0.74 | $0.03 | ||
| Q2 24 | $0.40 | $-0.03 | ||
| Q1 24 | $-0.83 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.1M | $14.7M |
| 总债务越低越好 | $771.2M | — |
| 股东权益账面价值 | $388.0M | $48.2M |
| 总资产 | $5.3B | $82.3M |
| 负债/权益比越低杠杆越低 | 1.99× | — |
8季度趋势，按日历期对齐
现金及短期投资NREFPLX
| Q4 25 | $31.1M | $14.7M | ||
| Q3 25 | $17.9M | $13.6M | ||
| Q2 25 | $9.1M | $17.9M | ||
| Q1 25 | $19.2M | $19.5M | ||
| Q4 24 | $3.9M | $19.8M | ||
| Q3 24 | $34.7M | $27.4M | ||
| Q2 24 | $4.3M | $23.4M | ||
| Q1 24 | $13.5M | — |
总债务NREFPLX
| Q4 25 | $771.2M | — | ||
| Q3 25 | $720.9M | — | ||
| Q2 25 | $815.6M | — | ||
| Q1 25 | $831.5M | — | ||
| Q4 24 | $799.3M | — | ||
| Q3 24 | $815.5M | — | ||
| Q2 24 | $861.0M | — | ||
| Q1 24 | $843.3M | — |
股东权益NREFPLX
| Q4 25 | $388.0M | $48.2M | ||
| Q3 25 | $375.4M | $52.9M | ||
| Q2 25 | $348.2M | $49.9M | ||
| Q1 25 | $343.7M | $45.2M | ||
| Q4 24 | $336.5M | $43.2M | ||
| Q3 24 | $335.8M | $32.4M | ||
| Q2 24 | $327.5M | $28.6M | ||
| Q1 24 | $327.1M | — |
总资产NREFPLX
| Q4 25 | $5.3B | $82.3M | ||
| Q3 25 | $5.3B | $82.3M | ||
| Q2 25 | $5.4B | $78.5M | ||
| Q1 25 | $5.4B | $73.9M | ||
| Q4 24 | $5.4B | $73.4M | ||
| Q3 24 | $5.7B | $61.6M | ||
| Q2 24 | $6.6B | $91.5M | ||
| Q1 24 | $7.1B | — |
负债/权益比NREFPLX
| Q4 25 | 1.99× | — | ||
| Q3 25 | 1.92× | — | ||
| Q2 25 | 2.34× | — | ||
| Q1 25 | 2.42× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.43× | — | ||
| Q2 24 | 2.63× | — | ||
| Q1 24 | 2.58× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.5M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | -0.19× | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流NREFPLX
| Q4 25 | $-4.5M | $2.0M | ||
| Q3 25 | $8.1M | $-3.7M | ||
| Q2 25 | $3.3M | $-5.2M | ||
| Q1 25 | $16.0M | $-5.1M | ||
| Q4 24 | $4.4M | $4.0M | ||
| Q3 24 | $14.7M | $4.1M | ||
| Q2 24 | $-7.5M | $-3.6M | ||
| Q1 24 | $17.7M | — |
自由现金流NREFPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率NREFPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度NREFPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率NREFPLX
| Q4 25 | -0.19× | — | ||
| Q3 25 | 0.16× | -1.58× | ||
| Q2 25 | 0.15× | -31.91× | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 0.29× | 0.61× | ||
| Q3 24 | 0.63× | 1.27× | ||
| Q2 24 | -0.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NREF
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
